# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

## **SCHEDULE 13G/A**

# Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

# **Abeona Therapeutics Inc.**

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

00289Y107 (CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b) ⊠ Rule 13d-1(c) □ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 9 Pages

1	NAME OF REPORTING PERSONS							
1	Great Point Partners, LLC							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) □							
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
Ŧ	Delaware							
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SOLE VOTING POWER 0					
BEN			SHARED VOTING POWER 0					
			SOLE DISPOSITIVE POWER 0					
			SHARED DISPOSITIVE POWER 0					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0							
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%							
12	TYPE OF REPORTING PERSON IA/OO (Limited Liability Company)							

SCHEDULE 13G/A

Page 3 of 9 Pages

	NAME OF REPORTING PERSONS						
1	Dr. Jeffrey R. Jay, M.D.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	USA						
		5 SOLE VOTING POWER					
S BEN	MBER OF SHARES EFICIALLY VNED BY	6	SHARED VOTING POWER 0				
RE	EACH PORTING PERSON WITH	7	SOLE DISPOSITIVE POWER 0				
	WIIII	8	SHARED DISPOSITIVE POWER 0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%						
12	TYPE OF REPORTING PERSON IN/HC						

SCHEDULE 13G/A

Page 4 of 9 Pages

1	NAME OF REPORTING PERSONS						
1	Mr. Ortav Yehudai						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION USA						
		5 SOLE VOTING POWER					
SI BENE	MBER OF HARES EFICIALLY VNED BY	6	SHARED VOTING POWER 0				
REI Pl	EACH PORTING ERSON WITH	7	SOLE DISPOSITIVE POWER 0				
	wiin	8	SHARED DISPOSITIVE POWER 0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%						
12	TYPE OF REPORTING PERSON IN/HC						

## Item 1. (a) Name of

## Issuer

Abeona Therapeutics Inc.

#### Item 1. (b) Address of Issuer's Principal Executive Offices

1330 Avenue of the Americas, New York, NY 10019

## Item 2. (a) Names of Persons Filing:

Great Point Partners, LLC ("Great Point") Dr. Jeffrey R. Jay, M.D. ("Dr. Jay") Mr. Ortav Yehudai ("Mr. Yehudai" and collectively with Great Point and Dr. Jay, the "Reporting Persons")

# Item 2. (b) Address of Principal Business Office:

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor Greenwich, CT 06830

## Item 2. (c) Citizenship:

Great Point is a limited liability company organized under the laws of the State of Delaware. Dr. Jay is a citizen of the United States. Mr. Yehudai is a citizen of the United States.

## Item 2. (d) Title of Class of Securities

Common Stock, par value \$0.01 per share

#### Item 2. (e) CUSIP No.:

00289Y107

CUSIP No. 00289Y107

SCHEDULE 13G/A

Page 6 of 9 Pages

#### Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) D Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
- (b)  $\square$  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  $\Box$  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) 🗆 Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  $\Box$  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  $\Box$  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  $\Box$  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) □ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  $\Box$  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) □ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:\_\_\_\_\_\_

CUSIP No. 00289Y107

SCHEDULE 13G/A

Page 7 of 9 Pages

#### Item 4. Ownership

The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference.

1. Great Point Partners, LLC

(a) Amount beneficially owned: 0

#### (b) Percent of class: 0%

#### (c) Number of shares as to which the person has:

- (i) Sole power to vote or direct the vote: 0
- (ii) Shared power to vote or direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to dispose or to direct the disposition of: 0

#### 2. Dr. Jeffrey R. Jay, M.D.

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or direct the vote: 0
  - (ii) Shared power to vote or direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0

#### 3. Mr. Ortav Yehudai

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or direct the vote: 0
  - (ii) Shared power to vote or direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0

## Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

#### Item 6. Ownership of More Than Five Percent on Behalf of Another Person See Item 4.

## Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group Not Applicable.

#### Item 9. Notice of Dissolution of Group

Not Applicable.

## Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### Exhibit List

A. Joint Filing Agreement, dated February 16, 2021, by and among the Reporting Persons (incorporated by reference to Exhibit 99.A of the Schedule 13G/A filed with the SEC by the Reporting Persons with respect to the Issuer on February 16, 2021).

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

## **Great Point Partners, LLC**

By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member

## Dr. Jeffrey R. Jay, M.D.

By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D.

#### Mr. Ortav Yehudai

By: /s/ Mr. Ortav Yehudai Mr. Ortav Yehudai

Exhibit A

#### JOINT FILING STATEMENT

## PURSUANT TO RULE 13d-1(k)

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: February 16, 2021

#### **Great Point Partners, LLC**

By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member

## Dr. Jeffrey R. Jay, M.D.

By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D.

#### Mr. Ortav Yehudai

By: /s/ Mr. Ortav Yehudai Mr. Ortav Yehudai